Clinical Trials

Cardioxyl has completed a Phase IIa dose-defining study to evaluate the hemodynamic effects, safety and tolerability of CXL-1020 in patients with acute decompensated heart failure (NCT01096043). Previously the company concluded a Phase I/IIa Dose-Escalation Study evaluating the safety and tolerability of CXL-1020 and specific effects on electrocardiographic and non-invasive hemodynamic parameters in patients with chronic heart failure (NCT01092325). More information is available on ClinicalTrials.gov.